Effects of Liquid Zinc Supplementation and Dispersible Zinc Tablets on Plasma Zinc Concentration
Sponsor
University of California, Davis (Other)
Overall Status
Completed
CT.gov ID
NCT00944853
Collaborator
Université Polytechnique de Bobo-Dioulasso (Other), Helen Keller International (Other), Nutriset (Industry)
462
1
3
6
76.4
Study Details
Study Description
Brief Summary
The study aims to compare the effects of two different formulations of zinc supplements on plasma zinc concentrations among young Burkinabe children.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
N/A |
Detailed Description
- To investigate the effects of short-term zinc supplementation, provided either as a dispersible tablet containing zinc sulfate ("ZinCfant," Nutriset Ltd; Malaunay, France) or as a liquid ZnSO4 solution, on changes in serum zinc concentration, compared with a placebo in young Burkinabe children; and 2) to assess the relationship between change in serum zinc concentration and the presence of altered intestinal permeability within each treatment group.
Study Design
Study Type:
Interventional
Actual Enrollment
:
462 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose:
Prevention
Official Title:
The Effect of Zinc Supplementation, Provided as Either a Liquid Zinc Solution or Dispersible Tablets, on Plasma Zinc Concentration Among Young Burkinabe Children
Study Start Date
:
Aug 1, 2009
Actual Primary Completion Date
:
Dec 1, 2009
Actual Study Completion Date
:
Feb 1, 2010
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Experimental: Zinc syrup Liquid Zinc Syrup (ZnSO4) solution provided daily |
Dietary Supplement: Liquid zinc syrup
Liquid zinc syrup containing 5 mg zinc as zinc sulfate
Other Names:
|
Experimental: Zinc tablet Dispersible zinc tablets provided daily |
Dietary Supplement: Zinc tablet
Dispersible zinc tablet containing 5 mg zinc
Other Names:
|
Placebo Comparator: Placebo Liquid placebo supplement provided daily |
Dietary Supplement: Liquid placebo supplement
Liquid placebo supplement containing 0 mg zinc
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Plasma zinc concentration [3 weeks]
Eligibility Criteria
Criteria
Ages Eligible for Study:
6 Months
to 23 Months
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
-
currently breast feeding
-
informed consent of a parent or guardian.
Exclusion Criteria:
-
symptomatic acute or chronic febrile infections
-
diarrhea within the past week
-
consuming vitamin or mineral supplements or zinc-fortified infant formulas
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Toussiana Health District | Toussiana | Burkina Faso |
Sponsors and Collaborators
- University of California, Davis
- Université Polytechnique de Bobo-Dioulasso
- Helen Keller International
- Nutriset
Investigators
- Principal Investigator: Kenneth H Brown, MD, University of California, Davis
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
University of California, Davis
ClinicalTrials.gov Identifier:
NCT00944853
Other Study ID Numbers:
- 200917272
- ZincTab
First Posted:
Jul 23, 2009
Last Update Posted:
Feb 24, 2017
Last Verified:
Feb 1, 2010
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by University of California, Davis
Additional relevant MeSH terms: